R

Ultragenyx Pharmaceutical
D

RARE

42.200
USD
-0.77
(-1.79%)
مفتوح الان
حجم التداول
6,804
الربح لكل سهم
-6
العائد الربحي
-
P/E
-7
حجم السوق
3,896,928,110
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLUE
    0.89000
    (10.55%)
    9.33000 USD
    C
    CLRB
    -0.01330
    (-5.39%)
    0.23360 USD
    C
    CRIS
    -0.16000
    (-4.97%)
    3.06000 USD
    F
    FATE
    0.02000
    (1.19%)
    1.70000 USD
    K
    KRYS
    3.790
    (2.42%)
    160.310 USD
    M
    MGTX
    -0.02000
    (-0.34%)
    5.83000 USD
    S
    SRPT
    -1.320
    (-1.10%)
    118.880 USD
    V
    VCEL
    -0.530
    (-0.94%)
    55.830 USD
    V
    VCYT
    -0.410
    (-1.04%)
    39.130 USD
    المزيد
الأخبار

العنوان: Ultragenyx Pharmaceutical

القطاع: Healthcare
الصناعة: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.